Surmodics reported $21M in Gross Profit on Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Abbott ABT:US $ 6908M 160M
Align Technology ALGN:US $ 709.35M 35.22M
Anika Therapeutics ANIK:US $ 21.8M 3.67M
Baxter International BAX:US $ 1350M 58M
Bioscrip BIOS:US $ 212.2M 9.23M
Boston Scientific BSX:US $ 2059M 85M
Edwards Lifesciences EW:US $ 1041.9M 21.7M
Johnson & Johnson JNJ:US $ 15828M 1021M
Merit Medical Systems MMSI:US $ 120.91M 7.9M
Mesa Laboratories MLAB:US $ 28.63M 5.49M
Nektar Therapeutics NKTR:US $ 18.85M 0.76M
Stryker SYK:US $ 2727M 272M
Surmodics SRDX:US $ 21M 2.49M